Elon Musk’s electric vehicles (EVs) manufacturing company, Tesla has leased 33,475 sq ft retail and service center space at Orchid Business Park, Sohna Road, Gurgaon for a monthly rental of Rs 40 lakh.
This will be company’s second showroom in India after Mumbai, where it has opened a showroom recently.
According to documents shared by data analytics firm CRE Matrix, Tesla has leased the space for 9 years with lease starting from July 15.
Tesla has paid Rs 2.41 crore as security deposit.
Earlier, the American multinational company had entered into an agreement with a Maker Group company to lease space on the ground floor of 2 North Avenue of commercial complex Maker Maxity at monthly rentals of Rs 881 per sq ft.
In Gurgaon, it will be paying Rs 120 per sq ft, however the Gurgaon area is almost ten times bigger than Mumbai.
Tesla has been actively exploring opportunities to enter the Indian market, aiming to introduce its popular range of electric vehicles to the country. The company has been in discussions with government authorities, scouting for showroom locations, and evaluating potential manufacturing sites to establish a strong foothold in one of the world's fastest-growing automobile markets.
ET has already reported that Tesla has begun scouting for land to set up an EV manufacturing plant and Maharashtra is the initial identified destination.
The company’s plans gathered steam after Tesla boss Musk met Prime Minister Narendra Modi earlier this year. According to reports, Musk has sought lower tariffs on imported EVs .
On September 10, 2025, Oracle Financial Services Software (OFSS) surged over 7% on Indian exchanges, driven primarily by its parent company Oracle Cor
The Flipkart Big Billion Days Sale 2025, starting September 23, is India’s ultimate festive shopping event, offering massive discounts on smartphones,
Life insurance providers are well-prepared to navigate the GST exemption on premiums, effective September 22, 2025. Despite the loss of input tax cred
Russia's Enteromix mRNA cancer vaccine achieved 100% efficacy in preclinical trials, effectively shrinking tumors. Initially targeting colorectal canc